Sharper blood test could uncover hidden cause of high blood pressure

NCT ID NCT07691801

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests whether a more precise lab technique (mass spectrometry) can improve the captopril test used to diagnose primary aldosteronism, a common but treatable cause of high blood pressure. Researchers will measure aldosterone and renin levels in blood samples from healthy volunteers and patients suspected of having the condition. The goal is to establish a new diagnostic cutoff that helps doctors identify this curable form of hypertension more accurately.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
captopril
What this could lead to
If successful, this could lead to a more accurate diagnostic test for primary aldosteronism, helping doctors identify a treatable cause of high blood pressure earlier.
What could go wrong
This is a diagnostic study, not a treatment trial. The new cutoff value may not prove significantly better than current methods, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY ALDOSTERONISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking Union Medical Colledge Hospital

    RECRUITING

    Beijing, Beijing Municipality, 456350, China

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.